What is Amunix Pharmaceuticals?
Founded in 2006 and headquartered in Mountain View, California, Amunix Pharmaceuticals is a specialized biopharmaceutical entity dedicated to the discovery and manufacturing of next-generation cancer therapeutics. The company distinguishes itself through its focus on developing potent, long-acting, and tumor-targeted therapies designed to improve the therapeutic index of potent anti-cancer agents. By leveraging advanced protein engineering, Amunix aims to minimize systemic toxicity while maximizing efficacy, positioning itself as a critical player in the evolving oncology landscape.
How much funding has Amunix Pharmaceuticals raised?
Amunix Pharmaceuticals has raised a total of $190M across 2 funding rounds:
Series A
$73M
Series B
$117M
Series A (2020): $73M with participation from Omega Funds, Longitude Capital, Venrock, Delian Capital, Casdin Capital, Redmile Group, Frazier Healthcare Partners, Two River, and Polaris Partners
Series B (2021): $117M led by Omega Funds, Longitude Capital, Venrock, Casdin Capital, The Clough Global Long/Short Fund, Redmile Group, Frazier Healthcare Partners, ArrowMark Partners, Avidity Partners, Bain Capital, Janus Henderson Investors, Caas Capital Management, Franklin Templeton, BlackRock, Viking Global Investors, and Polaris Partners
Key Investors in Amunix Pharmaceuticals
Omega Funds
Omega Funds is a specialized investment firm focused on the life sciences sector, providing capital to companies developing breakthrough medical technologies.
Longitude Capital
Longitude Capital is a healthcare-focused venture capital firm that invests in biotechnology and medical technology, pairing sector expertise with flexible capital to help innovators scale.
Venrock
Venrock is a historic venture capital firm that partners with founders to build high-growth companies, known for its deep industry expertise and commitment to healthcare innovation.
What's next for Amunix Pharmaceuticals?
With the recent influx of capital, Amunix Pharmaceuticals is well-positioned to transition its lead candidates through critical clinical milestones. The strategic focus will likely center on expanding its internal research capabilities and scaling manufacturing processes to support late-stage development. As the company continues to refine its platform, the emphasis remains on establishing partnerships and clinical data sets that validate its approach to precision oncology, ultimately aiming to deliver transformative outcomes for patients suffering from complex malignancies.
See full Amunix Pharmaceuticals company page
